Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
The objective of this study was to assess the prognostic relevance of preoperative serum anti-p53 antibodies in epithelial ovarian cancer. These autoantibodies were detected with a new generation enzyme-linked immunosorbent assay in blood samples preoperatively drawn from 86 patients with this malignancy. Serum anti-p53 antibodies were found in 3 (10.0%) of the 30 patients with stage I-II and 15 (26.8%) of the 56 patients with stage III-IV epithelial ovarian cancer (P = 0.09). We assessed in detail 44 patients with stage III-IV disease who underwent six cycles of first-line platinum-based chemotherapy. A pathological complete response at second-look was achieved by none of the 15 patients with serum anti-p53 antibodies compared to 24.1% of the 29 patients without autoantibodies (P = 0.09). However, the preoperative serum anti-p53 antibody status had no prognostic relevance for progression-free survival and survival. In conclusion, the assessment of preoperative serum anti-p53 antibodies seems to have a limited clinical value in the management of patients with advanced epithelial ovarian cancer.
Gadducci
A
A
Department of Procreative Medicine, Division of Gynecology and Obstetrics, University of Pisa, Via Roma 67, Pisa, 56127, Italy.
Ferdeghini
M
M
Buttitta
F
F
Cosio
S
S
Fanucchi
A
A
Annicchiarico
C
C
Gagetti
O
O
Bevilacqua
G
G
Genazzani
A R
AR
D001323:Autoantibodies / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000401:mortality*; D011379:Prognosis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D001323:Autoantibodies; D016159:Tumor Suppressor Protein p53